Basal Cell Carcinoma (BCC) Completed Phase 2 Trials for Vismodegib (DB08828)

Also known as: BCC - Basal Cell Carcinoma / Basal Cell Carcinomas / Basal Cell Carcinoma / Carcinoma basal cell / Basalioma / Basal cell epithelioma / Rodent ulcer / Basal cell carcinoma (morphologic abnormality) / Basal cell carcinoma of skin (disorder) / Carcinoma, Basal Cell

IndicationStatusPhase
DBCOND0040396 (Basal Cell Carcinoma (BCC))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03035188Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell CarcinomaTreatment
NCT02667574Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)Treatment
NCT01815840A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell CarcinomasTreatment
NCT01700049Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic SubtypesTreatment
NCT01543581Vismodegib for Treatment of Basal Cell CarcinomaTreatment
NCT01367665STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaTreatment
NCT01201915A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell CarcinomaTreatment
NCT00959647A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyTreatment
NCT00833417A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell CarcinomaTreatment